MEDHERANT

• 72110 - Research and experimental development on biotechnology

Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch®. The company's lead project is a testosterone patch for women. There is considerable interest in the transdermal delivery of drugs to overcome some of the disadvantages of oral administration, such as spikes in drug levels that can lead to side effects, and poor compliance. Patches are also a more convenient way to deliver drugs through the skin than gels and creams and provide better dose control... In addition to developing its own transdermal and topical products, Medherant is collaborating with third parties to formulate their drugs for transdermal delivery using its TEPI technology. In the future, Medherant expects to receive milestone payments and/or licence revenues for products utilising its technology... Medherant is creating a sustainable, next-generation transdermal drug delivery patch company that creates value for patients, partners..

Also known as: MEDHERANT LIMITED

Registration numbers: 08973262 (CH)

VAT numbers: GB206942510

Primary location: Coventry United Kingdom